1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine has been researched along with Parkinson Disease, Secondary in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 15 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Block, F; Clement, HW; Grote, C; Sontag, KH; Wesemann, W | 1 |
Altagracia, M; Kravzov, J; Rios, C; Rojas, P | 1 |
Bédard, PJ; Di Paolo, T; Gagnon, C; Gomez-Mancilla, B | 1 |
Herrero, MT; Laguna, J; Luquin, MR; Obeso, JA | 1 |
Kuno, S; Mizuta, E; Sasa, M; Yoshida, O; Yoshimura, N | 1 |
Hineno, T; Hiratani, K; Kakimoto, Y; Mizobuchi, M | 1 |
Samuelsson, EB; Sundström, E | 1 |
Camarata, PJ; Chae, H; Ebner, TJ; Haines, SJ; Park, SK; Parker, RG; Turner, DA | 1 |
Benazzouz, A; Bioulac, B; Dupont, J; Gross, C | 1 |
Alexander, GM; Brainard, L; Gordon, SW; Grothusen, JR; Schwartzman, RJ | 1 |
Bachurin, SO; Dubova, LG; Lermontova, NN; Sablin, SO; Solyakov, LS; Tkachenko, SE | 1 |
Filion, M; Tremblay, L | 1 |
Bédard, PJ; Filion, M; Tremblay, L | 1 |
McCrodden, JM; Sullivan, JP; Tipton, KF | 1 |
Bédard, PJ; Di Paolo, T; Rouillard, C | 1 |
1 review(s) available for 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine and Parkinson Disease, Secondary
Article | Year |
---|---|
The neurotoxicity of MPTP and the relevance to Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; MPTP Poisoning; Parkinson Disease, Secondary | 1990 |
14 other study(ies) available for 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine and Parkinson Disease, Secondary
Article | Year |
---|---|
Functional studies on monoaminergic transmitter release in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; Animals; Apomorphine; Biogenic Monoamines; Dopamine; Dopamine Agents; Dopamine Antagonists; Hydroxyindoleacetic Acid; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Rats; Rats, Wistar; Stereotyped Behavior; Tryptophan | 1993 |
Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Brain Chemistry; Corpus Striatum; Dopamine; Dopamine Agents; Homovanillic Acid; Hydroxyindoleacetic Acid; Male; Mice; Parkinson Disease, Secondary; Probenecid; Serotonin | 1993 |
Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Behavior, Animal; Brain Chemistry; Dopamine; Dopamine Agents; Dopamine D2 Receptor Antagonists; Female; GTP-Binding Proteins; Indoles; Macaca fascicularis; Neostriatum; Ovariectomy; Parkinson Disease, Secondary; Phenanthridines; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, GABA-A | 1993 |
Behavioral tolerance to repeated apomorphine administration in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Dopamine; Dopamine Agents; Drug Tolerance; Female; Macaca fascicularis; Male; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Psychomotor Performance | 1993 |
The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Dopamine Agents; Ergolines; Macaca fascicularis; Male; Parkinson Disease, Secondary; Quinpirole; Reflex; Urinary Bladder; Urination | 1993 |
Increase of plasma adrenocorticotrophin and cortisol in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated dogs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Glands; Adrenocorticotropic Hormone; Animals; Circadian Rhythm; Dogs; Dopamine Agents; Hydrocortisone; Hypothalamus; Male; Osmolar Concentration; Parkinson Disease, Secondary; Pituitary Gland | 1993 |
Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Dopamine; Lactic Acid; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Norepinephrine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Synaptosomes | 1997 |
Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced hemiparkinsonism on the kinematics of a two-dimensional,multijoint arm movement in the rhesus monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arm; Behavior, Animal; Carbidopa; Female; Levodopa; Macaca mulatta; Male; Movement; Parkinson Disease, Secondary; Reaction Time; Substantia Nigra; Tyrosine 3-Monooxygenase | 1992 |
MPTP induced hemiparkinsonism in monkeys: behavioral, mechanographic, electromyographic and immunohistochemical studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine Agents; Electromyography; Immunohistochemistry; Kinetics; Macaca mulatta; Muscles; Parkinson Disease, Secondary | 1992 |
Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Catecholamines; Dopamine; Dopamine Agents; Levodopa; Macaca fascicularis; Male; Mazindol; Parkinson Disease, Secondary; Receptors, Dopamine | 1992 |
Molecular basis of discrepancies in neurotoxic properties among 1-methyl-4-aryl-1,2,3,6-tetrahydropyridines.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Dopamine; Dopamine Agents; Guinea Pigs; In Vitro Techniques; Kinetics; Mice; Mice, Inbred C57BL; Mitochondria, Liver; Monoamine Oxidase; MPTP Poisoning; Nerve Degeneration; Neurons; Norepinephrine; Parkinson Disease, Secondary; Structure-Activity Relationship; Synaptosomes | 1992 |
Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Dopamine Agents; Electrophysiology; Female; Globus Pallidus; Macaca fascicularis; Medulla Oblongata; Neurons; Parkinson Disease, Secondary | 1991 |
Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Basal Ganglia; Dopamine Agents; Electrophysiology; Globus Pallidus; Macaca fascicularis; Motor Activity; Neurons; Parkinson Disease, Secondary; Phenethylamines | 1991 |
Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Brain; Brain Chemistry; Bromocriptine; Dopamine; Female; Homovanillic Acid; Kinetics; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Receptors, Dopamine; Spiperone | 1990 |